Duopharma Biotech expanding mobile breast cancer screening in Malaysia

Duopharma Biotech, a prominent pharmaceutical company in Malaysia, is taking significant steps to enhance access to a mobile breast cancer screening device at the community level. The company has recently entered into a distribution agreement with UE LifeSciences, the Malaysian division of a US-based femtech company, to make the revolutionary iBreastExam device readily available in primary care clinics throughout the country.

The iBreastExam device is a handheld, radiation-free tool that employs DCPC (Dynamic Co-Planar Capacitive) sensor technology to instantly measure breast tissue elasticity at the point of care. This user-friendly device requires minimal training and effectively identifies and prioritises clinically relevant breast lumps in asymptomatic patients. Moreover, it automates and standardises clinical breast examinations and stores data on the cloud, enabling seamless follow-up.

The accuracy of the iBreastExam device in the early detection of breast cancer has been corroborated by numerous independent clinical studies worldwide. UE LifeSciences has obtained regulatory approvals in more than 12 countries for the device, including clearance from the United States FDA and Europe's CE mark.

The initiative is of paramount importance for Malaysia, where nearly 40% of new breast cancer cases are diagnosed at an advanced stage each year. The survival rates for Stage 3 and Stage 4 cases are distressingly low, underlining the urgent need for early detection of breast cancer. By partnering with private and public health organisations and distributing iBreastExam devices across primary care clinics, Duopharma Biotech aims to tackle the issue of limited access to breast cancer detection and promote preliminary community screening.

Globally, the trend towards early cancer detection initiatives is leveraging the power of artificial intelligence (AI) to identify potential cases more effectively. Companies like Lunit, a medical AI firm based in South Korea, are contributing to large-scale programs, such as Australia's New South Wales' BreastScreen initiative and the breast cancer screening at Capio S:t Göran Hospital in Sweden, which is one of the largest healthcare providers in the country. The integration of AI in such endeavours is expected to further enhance the efficacy of early cancer detection and potentially save more lives.

Click here to read the original news story.